Although the treatment modalities for acute myeloid leukemia (AML) have not changed much over the past 40 years, distinct progress has been made in deciphering the basic biology underlying the pathogenesis of this group of hematological disorders. Studies show that AML development is a multicause, multistep and multipathway process. Accordingly, AMLs constitute a heterogeneous group of diseases. The thorough understanding of the molecular basis of AML is paving the way for better therapeutic approaches. Multiple novel drugs are being introduced and new, more efficient and less toxic formulations of conventional therapeutics are becoming available. Here, we review the recent advances in the comprehension of the molecular processes that lead to the onset of AML and its translation into clinical practice.

Understanding the molecular basis of acute myeloid leukemias : where are we now? / A. M Gruszka, D. Valli, M. Alcalay. - In: INTERNATIONAL JOURNAL OF HEMATOLOGIC ONCOLOGY. - ISSN 2045-1393. - 6:2(2017 Nov), pp. 43-53. [10.2217/ijh-2017-0002]

Understanding the molecular basis of acute myeloid leukemias : where are we now?

D. Valli
Secondo
;
M. Alcalay
Ultimo
2017-11

Abstract

Although the treatment modalities for acute myeloid leukemia (AML) have not changed much over the past 40 years, distinct progress has been made in deciphering the basic biology underlying the pathogenesis of this group of hematological disorders. Studies show that AML development is a multicause, multistep and multipathway process. Accordingly, AMLs constitute a heterogeneous group of diseases. The thorough understanding of the molecular basis of AML is paving the way for better therapeutic approaches. Multiple novel drugs are being introduced and new, more efficient and less toxic formulations of conventional therapeutics are becoming available. Here, we review the recent advances in the comprehension of the molecular processes that lead to the onset of AML and its translation into clinical practice.
AM;, leukemogenesis; molecular oncology
Settore MED/04 - Patologia Generale
Settore MED/03 - Genetica Medica
Settore MED/15 - Malattie del Sangue
Article (author)
File in questo prodotto:
File Dimensione Formato  
R11-IJH-Gruszka_17.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.78 MB
Formato Adobe PDF
1.78 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/551233
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact